Multimodality treatment with intensity modulated radiation therapy for esophageal cancer - PubMed (original) (raw)
Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
T H La et al. Dis Esophagus. 2010 May.
Abstract
The objective of this study is to determine the feasibility and report the outcome of patients with locally advanced esophageal cancer treated with preoperative or definitive chemoradiotherapy (CRT) using intensity-modulated radiation therapy (IMRT). Between 2003 and 2007, 30 patients with non-cervical esophageal cancer received concurrent chemotherapy and IMRT at Stanford University. Eighteen patients were planned for definitive CRT and 12 were planned for preoperative CRT. All patients had computed tomography-based treatment planning and received IMRT. The median dose delivered was 50.4 Gy. Patients planned for preoperative CRT underwent surgery 4-13 weeks (median 8.3 weeks) following completion of CRT. Median follow-up of surviving patients from start of RT was 24.2 months (range 8.2-38.3 months). The majority of tumors were adenocarcinomas (67%) and poorly differentiated (57%). Tumor location was 7% upper, 20% mid, 47% lower, and 27% gastroesophageal junction. Actuarial 2-year local-regional control (LRC) was 64%. High tumor grade was an adverse prognostic factor for LRC and overall survival (OS) (P= 0.015 and 0.012, respectively). The 2-year LRC was 83% vs. 51% for patients treated preoperatively vs. definitively (P= 0.32). The 2-year disease-free and OS were 38% and 56%, respectively. Twelve patients (40%) required feeding tube placement, and the average weight loss from baseline was 4.8%. Twelve (40%) patients experienced grade 3+ acute complications and one patient died of complications following feeding tube placement. Three patients (10%) required a treatment break. Eight patients (27%) experienced grade 3 late complications. No grade 4 complications were seen. IMRT was effective and well tolerated. Disease recurrence remains a challenge and further investigation with dose escalation to improve LRC and OS is warranted.
Similar articles
- Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Jin J, et al. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380576 - Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy.
Sher DJ, Thotakura V, Balboni TA, Norris CM Jr, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB. Sher DJ, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e215-22. doi: 10.1016/j.ijrobp.2011.02.023. Epub 2011 Apr 29. Int J Radiat Oncol Biol Phys. 2011. PMID: 21531515 - Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY. de Arruda FF, et al. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73. doi: 10.1016/j.ijrobp.2005.03.006. Epub 2005 May 31. Int J Radiat Oncol Biol Phys. 2006. PMID: 15925451 - Radiation therapy and esophageal cancer.
Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, Hoffe SE. Shridhar R, et al. Cancer Control. 2013 Apr;20(2):97-110. doi: 10.1177/107327481302000203. Cancer Control. 2013. PMID: 23571700 Review. - The use of chemoradiotherapy in oesophageal cancer.
Geh JI. Geh JI. Eur J Cancer. 2002 Jan;38(2):300-13. doi: 10.1016/s0959-8049(01)00353-7. Eur J Cancer. 2002. PMID: 11803146 Review.
Cited by
- Radiation Pneumonitis after Intensity-Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a Systematic Review.
Tonison JJ, Fischer SG, Viehrig M, Welz S, Boeke S, Zwirner K, Klumpp B, Braun LH, Zips D, Gani C. Tonison JJ, et al. Sci Rep. 2019 Feb 19;9(1):2255. doi: 10.1038/s41598-018-38414-5. Sci Rep. 2019. PMID: 30783157 Free PMC article. - Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.
Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Lin SH, et al. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1078-85. doi: 10.1016/j.ijrobp.2012.02.015. Epub 2012 Aug 3. Int J Radiat Oncol Biol Phys. 2012. PMID: 22867894 Free PMC article. - Volumetric-modulated arc therapy for the treatment of a large planning target volume in thoracic esophageal cancer.
Abbas AS, Moseley D, Kassam Z, Kim SM, Cho C. Abbas AS, et al. J Appl Clin Med Phys. 2013 May 6;14(3):4269. doi: 10.1120/jacmp.v14i3.4269. J Appl Clin Med Phys. 2013. PMID: 23652258 Free PMC article. - Increased risk of death due to heart disease after radiotherapy for esophageal cancer.
Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S. Frandsen J, et al. J Gastrointest Oncol. 2015 Oct;6(5):516-23. doi: 10.3978/j.issn.2078-6891.2015.040. J Gastrointest Oncol. 2015. PMID: 26487946 Free PMC article. - Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer.
Nguyen NP, Jang S, Vock J, Vinh-Hung V, Chi A, Vos P, Pugh J, Vo RA, Ceizyk M, Desai A, Smith-Raymond L; International Geriatric Radiotherapy Group. Nguyen NP, et al. BMC Cancer. 2014 Apr 17;14:265. doi: 10.1186/1471-2407-14-265. BMC Cancer. 2014. PMID: 24742268 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials